首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 以基因為基之藥物開發

表觀遺傳學市場規模、佔有率和成長分析（按產品、技術、方法、應用、最終用途和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1898713

表觀遺傳學市場規模、佔有率和成長分析（按產品、技術、方法、應用、最終用途和地區分類）—產業預測（2026-2033 年）

Epigenetics Market Size, Share, and Growth Analysis, By Product (Kits & Reagents, Instruments), By Technology (DNA Methylation, Histone Methylation), By Technique, By Application, By End-use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，表觀遺傳學市場規模將達到 18.4 億美元，到 2025 年將達到 21.1 億美元，到 2033 年將達到 63.6 億美元，在預測期（2026-2033 年）內，複合年成長率為 14.8%。

由於表觀遺傳學在增進我們對基因調控的理解（超越傳統DNA定序）、增強疾病監測以及促進個人化醫療方面發揮關鍵作用，因此該市場正經歷著顯著成長。預計投資的增加將進一步推動該行業的擴張。然而，全球癌症發生率的上升仍然是一個不容忽視的挑戰，每年導致數百萬新增病例和死亡。表觀遺傳疾病的治療利用多種標靶酵素的抑制劑，例如HDM、HMT、DNMT、HAT和HDAC，而免疫療法和化療等傳統治療方法則作為補充手段。表觀遺傳療法在治療癌症和神經系統疾病方面展現出巨大的潛力。在人們對癌症日益關注的背景下，這些因素共同推動了表觀遺傳學市場的強勁成長。

表觀遺傳學市場促進因素

表觀遺傳學市場的發展主要受多種慢性疾病（包括癌症和心血管疾病）發生率上升的驅動。 DNA甲基化和組蛋白修飾等表觀遺傳改變在這些疾病的進展和發展中起著關鍵作用。隨著精準醫療的日益普及，大量資金和研究投入正湧入表觀遺傳療法的研發，展現出個人化治療的巨大潛力。這一趨勢不僅凸顯了表觀遺傳學在現代醫療保健中的重要作用，也推動了相關產品和服務的需求，為該領域的蓬勃發展創造了良好的環境。

表觀遺傳學市場限制因素

エピジェネティクス市場は、研究開発および治療開発に伴う多額の費用により、重大な課題に直面しています。この分野は次世代定序やクロマチン免疫沉澱分析法といった高度な技術に大きく依存しており、これらは高い導入コストと運用コストを伴います。こうした財政的障壁は、特にヘルスケア予算が限られている発展途上地域において、必須のエピジェネティックツールや治療方法へのアクセスを制限しています。その結果、多くの機関や研究者がエピジェネティクスの進歩を十分に探求するために必要な資源に投資できないため、市場の成長可能性が阻害されています。この財政的制約は、エピジェネティックソリューションの全体的な発展とアクセシビリティに大きく影響しています。

表觀遺傳學市場趨勢

表觀遺傳學市場呈現顯著的發展趨勢，這主要得益於表觀遺傳編輯技術的進步。這些創新技術，包括基於 CRISPR/Cas9 的工具，使研究人員能夠精確地修飾表觀遺傳標記，從而在不改變 DNA 序列本身的情況下，對基因調控進行精細的研究。這種精準性為包括癌症、神經系統疾病和自體免疫疾病在內的多個醫學領域開發標靶治療創造了變革性的機會。隨著這些前沿工具的加速應用，表觀遺傳學研究的模式有望發生巨大變化，從而推動新療法的開發，並加深我們對複雜生物過程的理解。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Thermo Fisher Scientific Inc.（United States）
Illumina, Inc.（United States）
Merck KGaA（Germany）
QIAGEN NV（Netherlands）
Pacific Biosciences of California, Inc.（United States）
Bio-Rad Laboratories, Inc.（United States）
PerkinElmer, Inc.（United States）
10x Genomics, Inc.（United States）
Active Motif, Inc.（United States）
Zymo Research Corporation（United States）
New England Biolabs, Inc.（United States）
Promega Corporation（United States）
Novartis AG（Switzerland）
Element Biosciences, Inc.（United States）
Dovetail Genomics LLC（United States）
Storm Therapeutics（United Kingdom）

結論與建議

簡介目錄

Product Code: SQMIG35H2201

Epigenetics Market size was valued at USD 1.84 Billion in 2024 and is poised to grow from USD 2.11 Billion in 2025 to USD 6.36 Billion by 2033, growing at a CAGR of 14.8% during the forecast period (2026-2033).

The epigenetics market is witnessing significant growth due to its critical role in advancing gene regulation knowledge beyond traditional DNA sequencing, enhancing disease research, and facilitating personalized medicine. Increased investments are anticipated to further propel industry expansion. However, the escalating global cancer prevalence presents a notable challenge, with millions of new cases and fatalities reported annually. Various inhibitors targeting enzymes such as HDM, HMT, DNMT, HAT, and HDAC are being utilized for epigenetic disorders, while traditional treatments like immunotherapy and chemotherapy complement these approaches. The potential of epigenetic therapy is promising, particularly in addressing cancer and neurological diseases. Collectively, these factors indicate a robust growth trajectory for the epigenetics market amidst rising cancer concerns.

Top-down and bottom-up approaches were used to estimate and validate the size of the Epigenetics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Epigenetics Market Segments Analysis

Global Epigenetics Market is segmented by Product, Technology, Technique, Application, End-use and region. Based on Product, the market is segmented into Kits & Reagents, Instruments, Enzymes and Services. Based on Technology, the market is segmented into DNA Methylation, Histone Methylation, Histone Acetylation, Large non-coding RNA, MicroRNA modification and Chromatin structures. Based on Technique, the market is segmented into NGS, PCR & QPCR, Mass Spectrometry, Sonication and Other Techniques. Based on Application, the market is segmented into Oncology and Non-oncology oncology. Based on End-use, the market is segmented into Academic Research, Clinical Research, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies and Other Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Epigenetics Market

The epigenetics market is significantly propelled by the increasing incidence of cancer and various chronic diseases, including cardiovascular conditions. Epigenetic changes, including DNA methylation and histone modifications, are crucial in the progression and development associated with these diseases. As the focus on precision medicine continues to grow, substantial financial and research investments are directed toward developing epigenetic therapies, showcasing their potential for personalized treatment options. This trend not only highlights the critical role of epigenetics in modern healthcare but also boosts the demand for related products and services, creating a thriving landscape for advancements in this field.

Restraints in the Epigenetics Market

The epigenetics market faces significant challenges due to the substantial expenses associated with research and therapeutic development. The field relies heavily on advanced technologies such as next-generation sequencing and chromatin immunoprecipitation, which come with high acquisition and operational costs. These financial barriers restrict access to essential epigenetic tools and therapies, particularly in developing regions where healthcare budgets are limited. As a result, the growth potential of the market is hindered, as many institutions and researchers are unable to invest in the necessary resources to explore epigenetic advancements fully. This financial constraint greatly influences the overall development and accessibility of epigenetic solutions.

Market Trends of the Epigenetics Market

The epigenetics market is experiencing a notable trend driven by advancements in epigenetic editing technologies. These innovations, including CRISPR/Cas9-based tools, empower researchers to precisely modify epigenetic marks, facilitating the nuanced study of gene regulation without changing the DNA sequence itself. This precision opens up transformative opportunities for developing targeted therapies across various medical domains, including cancer, neurological diseases, and autoimmune disorders. As adoption of these cutting-edge tools accelerates, the landscape of epigenetic research is set to evolve dramatically, paving the way for new treatment modalities and enhancing our understanding of complex biological processes.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Epigenetics Market Size by Product & CAGR (2026-2033)

Market Overview
Kits & Reagents
- Antibodies
- ChIP sequencing kit
- Whole Genomic Amplification kit
- Bisulfite Conversion kit
- RNA sequencing kit
- 5-HMC & 5-MC Analysis Kits& Reagents
- Histones
- Others
Instruments
Enzymes
- Dna-Modifying Enzymes
- Protein-Modifying Enzymes
- Other Enzymes
Services

Global Epigenetics Market Size by Technology & CAGR (2026-2033)

Market Overview
DNA Methylation
Histone Methylation
Histone Acetylation
Large non-coding RNA
MicroRNA modification
Chromatin structures

Global Epigenetics Market Size by Technique & CAGR (2026-2033)

Market Overview
NGS
PCR & QPCR
Mass Spectrometry
Sonication
Other Techniques

Global Epigenetics Market Size by Application & CAGR (2026-2033)

Market Overview
Oncology
- Solid tumors
- Liquid tumors
Non-oncology oncology
- Inflammatory diseases
- Metabolic diseases
- Infectious diseases
- Cardiovascular diseases
- Others

Global Epigenetics Market Size by End-use & CAGR (2026-2033)

Market Overview
Academic Research
Clinical Research
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Other Users

Global Epigenetics Market Size & CAGR (2026-2033)

North America (Product, Technology, Technique, Application, End-use)
- US
- Canada
Europe (Product, Technology, Technique, Application, End-use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Technology, Technique, Application, End-use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Technology, Technique, Application, End-use)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Technology, Technique, Application, End-use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Thermo Fisher Scientific Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pacific Biosciences of California, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
10x Genomics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Active Motif, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymo Research Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
New England Biolabs, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Promega Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Element Biosciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dovetail Genomics LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Storm Therapeutics (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments